C

an drug prices swing an election? Is every quarter a “great quarter“? And why is everyone freaking out about CRISPR?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation with cancer patient and drug pricing advocate David Mitchell about his group’s work to target pharma in the midterm elections. Then we’ll dig into everything you need to know ahead of a busy earnings season for the drug industry. STAT’s Sharon Begley stops by to explain the latest concerns over CRISPR — and why it has brought out such internet vitriol. And finally we’ll talk about the financial well-being of Martin Shkreli’s drug company, a surprising move from the Trump administration, and the year’s biggest biotech IPO.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy